IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases

Jingjing Zhao; Sarah Turpin-Nolan; Mark A Febbraio

doi:10.1016/j.cyto.2021.155549

IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases

Cytokine. 2021 Aug:144:155549. doi: 10.1016/j.cyto.2021.155549. Epub 2021 May 4.

Authors

Jingjing Zhao¹, Sarah Turpin-Nolan¹, Mark A Febbraio²

Affiliations

¹ Cellular & Molecular Metabolism Laboratory, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
² Cellular & Molecular Metabolism Laboratory, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia. Electronic address: mark.febbraio@monash.edu.

PMID: 33962843
DOI: 10.1016/j.cyto.2021.155549

Abstract

Metabolic disease is highly prevalent. Here we discuss the therapeutic utility of using gp130 receptor ligands as a therapeutic strategy to treat metabolic disease.

Keywords: Gp130 ligands; IL-6; Metabolic disease.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Cytokine Receptor gp130 / metabolism
Cytokines / metabolism*
Humans
Interleukin-6 / metabolism*
Metabolic Diseases / metabolism*
Signal Transduction / physiology

Substances

Cytokines
Interleukin-6
Cytokine Receptor gp130